Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to new inhibitors of peptide deformylase (PDF). These compounds are of great interest in particular as antibiotics.
• Peptide deformylase is a bacterial metalloenzyme which contains iron. It is detectable in all bacteria and plays a vital role in bacterial metabolism. During protein synthesis, peptide deformylase catalyses the removal of the formyl group from the N-terminus of bacterial proteins. Without the enzyme, bacteria cannot produce any functioning proteins. Peptide deformylase is the point of application of a new class of antibiotics, which are called peptide deformylase inhibitors.
• the present invention relates to compounds of formula (I),
• the radicals R 1 , R 2 , R 3 and R 4 are a hydrogen atom, a halogen atom, a hydroxy, amino, nitro or thiole group, an alkyl, alkenyl, alkinyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or a heteroaralkyl radical, whereby all of these radicals may optionally be substituted, or two of the radicals R 1 , R 2 , R 3 and R 4 together may be part of a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring, whereby each of these rings may optionally be substituted;
• R 5 is a hydrogen atom, a halogen atom, a hydroxy, amino, nitro or thiole group, an alkyl, alkenyl, alkinyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical;
• radicals R 6 and R 7 independently of one another, are a hydrogen atom, or an alkyl, alkenyl, alkinyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical; and
• X is a group of formula —CS—NHOH, —CH 2 —CO—CH 2 —OH, —CO—CH 2 —OH, —CO—NHOH, —CNH—NHOH, —CH 2 —NOH—CHS, —NOH—CHS, —NOH—CHO, —CH 2 —NOH—CHO, —CH 2 —NOH—CHO, —CH 2 —CHOH—CHO, —CHOH—COOH, —CH(CH 2 —OH)—COOH, —COOH or —CH 2 COOH, or is selected from the following formulae:
• U is a bond, CH 2 , NH, O or S
• V is O, S, NH or CH 2
• W is O, S, NH or CH 2
• Y is OH or NH 2
• E is a bond, CH 2 , NH, O or S and the groups D, G and M, independently of one another, are N or CH,
• alkyl refers to a saturated, straight-chained or branched hydrocarbon group, which has in particular 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, most preferably 1 to 6 carbon atoms, e.g. the methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, 2,2-dimethylbutyl or n-octyl group.
• alkenyl and alkinyl refer to at least partly unsaturated, straight-chained or branched hydrocarbon groups, which have in particular 2 to 20 carbon atoms, preferably 2 to 12 carbon atoms, most preferably 2 to 6 carbon atoms, e.g. the ethenyl, allyl, acetylenyl, propargyl, isoprenyl or hex-2-enyl group.
• Alkenyl groups preferably have one or two (most preferably one) double bond(s) and the alkinyl groups have one or two (most preferably one) triple bond(s).
• alkyl, alkenyl and alkinyl refer to groups, in which e.g. one or more hydrogen atoms are replaced by a halogen atom (preferably F or Cl), —COOH, —OH, —SH, —NH 2 , —NO 2 , ⁇ O, ⁇ S, ⁇ NH, such as the 2,2,2-trichloroethyl or the trifluoromethyl group.
• a halogen atom preferably F or Cl
• heteroalkyl refers to an alkyl, alkenyl or alkinyl group, in which one or more (preferably 1, 2 or 3) carbon atoms are replaced by an oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulfur atom (preferably oxygen, sulfur or nitrogen).
• the expression heteroalkyl refers furthermore to a carboxylic acid or a group derived from a carboxylic acid, such as acyl, acylalkyl, alkoxycarbonyl, acyloxy, acyloxyalkyl, carboxyalkylamide or alkoxycarbonyloxy.
• heteroalkyl groups are groups of formulae R a —O—Y a —, R a —S—Y a —, R a —N(R b )—Y a —, R a —CO—Y a —, R a —O—CO—Y a —, R a —CO—O—Y a —, R a —CO—N(R b )—Y a —, R a —N(R b )—CO—Y a —, R a —O—CO—N(R b )—Y a —, R a —N(R b )—CO—O—Y a —, R a —N(R b )—CO—O—Y a —, R a —N(R b )—CO—N(R c )—Y a —, R a —O—CO—O—Y a —
• heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, methoxyethyl, methylamino, ethylamino, dimethylamino, diethylamino, iso-propylethylamino, methyl-aminomethyl, ethylaminomethyl, di-iso-propylaminoethyl, enolether, dimethylaminomethyl, dimethylaminoethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl, ethoxy-carbonyl, N-ethyl-N-methylcarbamoyl or N-methylcarbamoyl.
• heteroalkyl groups are nitrile, isonitrile, cyanate, thiocyan
• cycloalkyl refers to a saturated or partially unsaturated (e.g. cycloalkenyl) cyclic group, which contains one or more rings (preferably 1 or 2), with in particular 3 to 14 ring carbon atoms, preferably 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms.
• cycloalkyl further refers to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine, bromine or iodine atoms or —COOH, —OH, ⁇ O, —SH, ⁇ S, —NH 2 , ⁇ NH or —NO 2 groups, that is, for example, cyclic ketones such as cyclohexanone, 2-cyclohexenone or cyclopentanone.
• cycloalkyl groups are the cyclopropyl, cyclobutyl, cyclopentyl, spiro[4,5]decanyl, norbornyl, cyclohexyl, cyclopentenyl, cyclohexadienyl, decalinyl, cubanyl, bicyclo[4.3.0]nonyl, tetraline, cyclopentylcyclohexyl, fluorocyclohexyl or the cyclohex-2-enyl group.
• heterocycloalkyl refers to a cycloalkyl group as defined above, in which one or more (preferably 1, 2 or 3) ring carbon atoms are replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably oxygen, sulfur or nitrogen).
• a heterocycloalkyl group preferably possesses 1 or 2 rings with 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms.
• the expression heterocycloalkyl further refers to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine, bromine or iodine atoms or —COOH, —OH, ⁇ O, —SH, ⁇ S, —NH 2 , ⁇ NH or —NO 2 groups.
• Examples are the piperidyl, morpholinyl, urotropinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydro-furyl, oxacyclopropyl, azacyclopropyl or 2-pyrazolinyl group, as well as lactams, lactones, cyclic imides and cyclic anhydrides.
• alkylcycloalkyl refers to group which, in accordance with the above definitions, contain both cycloalkyl and alkyl, alkenyl or alkinyl groups, e.g. alkylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkyl and alkinylcycloalkyl groups.
• An alkylcycloalkyl group preferably contains a cycloalkyl group which has one or two rings with 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms, and one or two alkyl, alkenyl or alkinyl groups with 1 or 2 to 6 carbon atoms.
• heteroalkylcycloalkyl refers to alkylcycloalkyl groups as defined above, in which one or more (preferably 1, 2 or 3) ring carbon atoms and/or carbon atoms are replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably oxygen, sulfur or nitrogen).
• a heteroalkylcycloalkyl group preferably possesses 1 or 2 rings with 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms and one or two alkyl, alkenyl, alkinyl or heteroalkyl groups with 1 or 2 to 6 carbon atoms.
• Examples of such groups are alkylheterocycloalkyl, alkylheterocycloalkenyl, alkenylheterocycloalkyl, alkinylheterocycloalkyl, heteroalkylcycloalkyl, heteroalkylheterocycloalkyl and hetero-alkylheterocylcloalkenyl, whereby the cyclic groups are saturated or are mono-, di- or tri-unsaturated.
• aryl or Ar refers to an aromatic group, which has one or more rings with in particular 6 to 14 ring carbon atoms, preferably 6 to 10 (especially 6) ring carbon atoms.
• aryl (or Ar) further refers to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine, bromine or iodine atoms or —COOH, —OH, —SH, —NH 2 , or —NO 2 groups. Examples are the phenyl, naphthyl, biphenyl, 2-fluorophenyl, anilinyl, 3-nitrophenyl or 4-hydroxyphenyl group.
• heteroaryl refers to an aromatic group which contains one or more rings with in particular 5 to 14 ring atoms, preferably 5 to 10 (especially 5 or 6) ring atoms, and one or more (preferably 1, 2, 3 or 4) oxygen, nitrogen, phosphorus or sulfur ring atoms (preferably O, S or N).
• heteroaryl further refers to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine, bromine or iodine atoms or —COOH, —OH, —SH, —NH 2 or —NO 2 groups.
• Examples are 4-pyridyl, 2-imidazolyl, 3-phenylpyrrolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl, pyridazinyl, quinolinyl, purinyl, carbazolyl, acridinyl, pyrimidyl, 2,3-bifuryl, 3-pyrazolyl and isoquinolinyl groups.
• aralkyl refers to groups which, in accordance with the above definitions, contain both aryl and alkyl, alkenyl, alkinyl and/or cycloalkyl groups, such as arylalkyl, alkylaryl, arylalkenyl, arylalkinyl, arylcycloalkyl, arylcycloalkenyl, alkylarylcycloalkyl and alkylarylcycloalkenyl groups.
• aralkyls are toluene, xylene, mesitylene, styrene, benzyl chloride, o-fluorotoluene, 1H-indene, tetraline, dihydronaphthalene, indanone, phenylcyclopentyl, cumene, cyclohexylphenyl, fluorene and indane.
• An aralkyl group preferably contains one or two aromatic rings with 6 to 10 ring carbon atoms and one or two alkyl, alkenyl and/or alkinyl groups with 1 or 2 to 6 carbon atoms and/or a cycloalkyl group with 5 or 6 ring carbon atoms.
• heteroaralkyl refers to an aralkyl group as defined above, in which one or more (preferably 1, 2, 3 or 4) ring carbon atoms and/or carbon atoms are replaced by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulfur atom (preferably oxygen, sulfur or nitrogen), i.e. it refers to groups which, in accordance with the above definitions, contain both aryl or heteroaryl, and alkyl, alkenyl, alkinyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups.
• a heteroaralkyl group preferably contains one or two aromatic rings with 5 or 6 to 10 ring carbon atoms and one or two alkyl, alkenyl and/or alkinyl groups with 1 or 2 to 6 carbon atoms and/or a cycloalkyl group with 5 or 6 ring carbon atoms, whereby 1, 2, 3 or 4 of these carbon atoms are replaced by oxygen, sulfur or nitrogen atoms.
• Examples are arylheteroalkyl, arylheterocycloalkyl, arylheterocycloalkenyl, arylalkylheterocycloalkyl, arylalkenylheterocycloalkyl, arylalkinylheterocycloalkyl, aryl-alkylheterocycloalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkinyl, heteroarylheteroalkyl, heteroarylcycloalkyl, heteroarylcycloalkenyl, heteroarylhetero-cycloalkyl, heteroarylheterocycloalkenyl, heteroarylalkylcycloalkyl, heteroarylalkylheterocycloalkenyl, heteroarylalkylcycloalkyl, heteroarylalkylheterocycloalkenyl, heteroarylalkylcycloalkyl, heteroarylalkylhe
• cycloalkyl hereocycloalkyl, alkylcyclo-alkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl and heteroaralky further refer to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine, bromine or iodine atoms or OH, ⁇ O, SH, ⁇ S, NH 2 , ⁇ NH or NO 2 groups.
• optionally substituted refers to groups in which one or more hydrogen atoms are replaced e.g. by fluorine, chlorine, bromine or iodine atoms or —COOH, —OH, ⁇ O, —SH, ⁇ S, —NH 2 , ⁇ NH or —NO 2 groups.
• This expression further refers to groups that are substituted by unsubstituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkinyl, C 1 -C 6 heteroalkyl, C 3 -C 10 cycloalkyl, C 2 -C 9 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 9 heteroaryl, C 7 -C 12 aralkyl or C 2 -C 11 heteroaralkyl groups.
• Compounds of formula (I) may contain one or more centres of chirality depending on their substitution.
• the present invention therefore includes both all pure enantiomers and all pure diastereoisomers, and their mixtures in any ratio.
• the present invention also includes all cis/trans isomers of the compounds of the general formula (I) as well as mixtures thereof.
• the present invention includes all tautomeric forms of the compounds of formula (I).
• X is a group of formula —CH 2 —CO—NHOH, —CO—NHOH, —CH 2 —NOH—CHS, —NOH—CHS, —CH 2 —NOH—CHO, —NOH—CHO, —CH 2 —CO—CH 2 OH, —CO—CH 2 OH, —CH 2 —CHOH—CHO, —CHOH—CHO or a group having one of the following formulae:
• X is most preferably a group of formula —CO—NHOH.
• R 1 is preferably a hydrogen atom, a chlorine atom, a bromine atom, an amino group, a methyl group or an ethyl group; especially a hydrogen atom or an amino group.
• R 2 is more preferably a hydrogen atom, a chlorine atom, a bromine atom, a methyl group or an ethyl group; especially a hydrogen atom.
• R 3 and R 4 are preferably not hydrogen atoms at the same time.
• R 3 is more preferably a hydrogen atom, a chlorine atom, a bromine atom, an amino group, a methyl group, an ethyl group or a propyl group, especially a chlorine atom, a bromine atom or an amino group.
• R 4 is, in turn, preferably a chlorine atom, a bromine atom, a methyl group, an ethyl group or a propyl group; especially a chlorine atom or a bromine atom.
• radicals R 1 , R 2 , R 3 and R 4 together are part of a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring, whereby each of these rings may optionally be substituted.
• R 5 is, in turn, preferably a tert.-butyl group, an isopropyl group, a neopentyl group or a n-hexyl group; especially a tert.-butyl, neopentyl or n-hexyl group.
• the groups R 6 and R 7 are hydrogen atoms, hydroxymethyl or methyl groups.
• Examples of pharmacologically acceptable salts of compounds of formula (I) are salts of physiologically acceptable mineral acids, such as hydrochloric acid, sulfuric acid and phosphoric acid; or salts of organic acids, such as methanesulfonic acid, p-toluene-sulfonic acid, lactic acid, formic acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.
• Compounds of formula (I) may be solvated, in particular hydrated. Hydration may arise e.g. during the preparation process or as a consequence of the hygroscopic nature of the initially water-free compounds of formula (I).
• compositions according to the present invention contain at least one compound of formula (I) as active ingredient and optionally carriers and/or adjuvants.
• the prodrugs (for definition and examples see e.g. R. B. Silverman, Medizinische Chemie, VCH Weinheim, 1995, chapter 8, pp 361ff), which are likewise an object of the present invention, contain a compound of formula (I) and at least one pharmacologically acceptable protecting group, which is cleaved under physiological conditions, e.g. a hydroxy, alkoxy, aralkyloxy, acyl or acyloxy group, such as a methoxy, ethoxy, benzyloxy, acetyl or acetyloxy group.
• a pharmacologically acceptable protecting group which is cleaved under physiological conditions, e.g. a hydroxy, alkoxy, aralkyloxy, acyl or acyloxy group, such as a methoxy, ethoxy, benzyloxy, acetyl or acetyloxy group.
• compounds of formula (I) are of great interest especially as inhibitors of metalloproteinases (in particular PDF).
• compounds of formula (I) are administered using known, acceptable methods, either singly or in combination with any other therapeutic agent. Administration may be effected e.g. in one of the following ways: orally, e.g. as dragées, coated tablets, pills, semi-solids, soft or hard capsules, solutions, emulsions or suspensions; parenterally, e.g. as an injectable solution; rectally as suppositories; by inhalation, e.g.
• the therapeutically employable product may be mixed with pharmacologically inert, inorganic or organic carriers for medicaments, e.g. with lactose, sucrose, glucose, gelatin, malt, silica gel, starch or derivatives thereof, talc, stearic acid or salts thereof, dry skimmed milk and the like.
• carriers for medicaments such as vegetable oils, petroleum, animal or synthetic oils, wax, fat, polyols, may be used.
• carriers for medicaments such as water, alcohols, aqueous salt solution, aqueous dextrose, polyols, glycerol, vegetable oils, petroleum, animal or synthetic oils
• carriers for medicaments such as vegetable oils, petroleum, animal or synthetic oils, wax, fat and polyols
• compressed gases that are appropriate for this purpose may be used, such as oxygen, nitrogen and carbon dioxide.
• the pharmaceutically acceptable agents may also contain preserving and stabilizing additives, emulsifiers, sweeteners, aromatics, salts to modify the osmotic pressure, buffers, coating additives and antioxidants.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (4)

Publications (2)

Family

ID=36692610

Family Applications (2)

Family Applications After (1)

Country Status (12)

Families Citing this family (13)

Citations (6)

Family Cites Families (6)

• 2005
  • 2005-04-25 DE DE102005019181A patent/DE102005019181A1/de not_active Withdrawn
• 2006
  • 2006-04-24 KR KR1020077024438A patent/KR20080002867A/ko not_active Ceased
  • 2006-04-24 BR BRPI0609946-7A patent/BRPI0609946A2/pt not_active IP Right Cessation
  • 2006-04-24 MX MX2007013225A patent/MX2007013225A/es active IP Right Grant
  • 2006-04-24 CN CN2006800139164A patent/CN101163703B/zh not_active Expired - Fee Related
  • 2006-04-24 EP EP06742663A patent/EP1877408A1/en not_active Withdrawn
  • 2006-04-24 RU RU2007143512/04A patent/RU2420526C2/ru not_active IP Right Cessation
  • 2006-04-24 AU AU2006239548A patent/AU2006239548B8/en not_active Ceased
  • 2006-04-24 JP JP2008508134A patent/JP2008538778A/ja active Pending
  • 2006-04-24 US US11/912,325 patent/US7662833B2/en not_active Expired - Fee Related
  • 2006-04-24 CA CA002605925A patent/CA2605925A1/en not_active Abandoned
  • 2006-04-24 US US11/912,555 patent/US20090215816A1/en not_active Abandoned
  • 2006-04-24 WO PCT/EP2006/003767 patent/WO2006114263A1/en not_active Ceased

Patent Citations (6)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events